argenx SE/$ARGX
1D1W1MYTD1Y5YMAX
Capital at risk
About argenx SE
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
- Ticker
- $ARGX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,863
- Headquarters
- Amsterdam, Netherlands
- Website
- argenx.com
argenx SE Metrics
BasicAdvanced
$63B
38.42
$26.21
-0.02
-
Price and volume
Market cap
$63B
Beta
-0.02
52-week high
$1,072.75
52-week low
$661.85
Average daily volume
282K
Financial strength
Current ratio
5.123
Quick ratio
4.524
Long term debt to equity
0.428
Total debt to equity
0.558
Interest coverage (TTM)
504.45%
Profitability
EBITDA (TTM)
1,612.902
Gross margin (TTM)
59.07%
Net profit margin (TTM)
32.26%
Operating margin (TTM)
30.13%
Effective tax rate (TTM)
1.81%
Revenue per employee (TTM)
$2,850,000
Management effectiveness
Return on assets (TTM)
11.63%
Return on equity (TTM)
23.63%
Valuation
Price to earnings (TTM)
38.417
Price to revenue (TTM)
11.722
Price to book
6.43
Price to tangible book (TTM)
6.64
Price to free cash flow (TTM)
68.962
Free cash flow yield (TTM)
1.45%
Free cash flow per share (TTM)
14.603
Growth
Revenue change (TTM)
70.30%
Earnings per share change (TTM)
39.82%
3-year revenue growth (CAGR)
85.31%
10-year revenue growth (CAGR)
80.64%
3-year earnings per share growth (CAGR)
54.19%
10-year earnings per share growth (CAGR)
37.57%
Bulls say / Bears say
Q2 2026 Vyvgart sales reached $1.516 billion, a 60 percent year-over-year increase, underscoring robust demand in generalized myasthenia gravis and CIDP. (Reuters via MarketScreener)
Gross margins expanded to approximately 33 percent in Q2 2026, up from 30 percent in Q1 2026, with analysts projecting potential to exceed industry averages if operational excellence is maintained. (Reuters via MarketScreener)
Topline results from the registrational ALKIVIA myositis study are on track for Q3 2026, providing a key catalyst for Vyvgart’s expansion into rheumatology. (Argenx Press Release)
Total operating expenses surged to $1.048 billion in Q2 2026 while R&D expenses rose to $486 million from $330 million a year earlier, potentially pressuring profitability if high spending levels persist. (Argenx Press Release)
Argenx faces binary risk with two pivotal registrational readouts—ALKIVIA for autoimmune myositis in Q3 2026 and EMPASSION for multifocal motor neuropathy in Q4 2026—that could materially impact its growth trajectory if results disappoint. (Argenx Press Release)
Shares trade near the top of their 52-week range, with premarket prices around $773.2 (52-week high $833.6), suggesting limited upside and elevated valuation risk. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 17 Aug 2026.
Upcoming events
No upcoming events
argenx SE News
AllArticlesVideos
These Analysts Boost Their Forecasts On Argenx
Benzinga3 weeks ago
argenx VYVGART Hits Phase III Goal in Autoimmune Myositis, Eyes IMNM Filing
MarketBeat3 weeks ago
Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
Business Wire3 weeks ago
Funds containing argenx SE
AllUSDGBPEUR
Fund name | Fund size | $ARGX weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 1.69% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 1.69% |
Vanguard FTSE Developed Europe ex UK€VERX | €3.4B | 0.47% |
Vanguard FTSE Developed Europe ex UK£VERX | £2.9B | 0.47% |
Vanguard FTSE Developed Europe€VWCG | €3.1B | 0.35% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.